Costa Rica’s Social Security Administration (CCSS) is conducting technical studies to determine the most suitable GLP-1 molecule for treating diabetic patients with obesity. The CCSS aims to identify the best option among medications currently available in private pharmacies under the brand names Ozempic, Mounjaro, and Wegovy. These medications are being evaluated for their potential to address health needs within the country’s population struggling with both diabetes and obesity. The studies will analyze the effectiveness and suitability of each drug to inform future healthcare provisions. This initiative underscores the CCSS’s commitment to evidence-based medicine and optimizing patient care. The ultimate goal is to provide the most effective treatment options for this specific patient group in Costa Rica. Access to these medications currently relies on purchase through private pharmacies.